Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NuPathe closes $30mm Series B round

Executive Summary

NuPathe (transdermal patch and implantable drug delivery technologies for CNS conditions) raised $30mm through a Series B round that was led by Quaker BioVentures and GlaxoSmithKline's venture arm SR One. Previous backers Safeguard Scientifics, Bay City Capital/Birchmere Ventures, Battelle Ventures, and BioAdvance Ventures also participated. A principal from SR One will join NuPathe's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
  • Medical Devices
    • Biomaterials
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies